{
  "nctId": "NCT06048471",
  "briefTitle": "High Tone Therapy for Chemotherapy Induced Neuropathy",
  "officialTitle": "High Tone Therapy for Chemotherapy Induced Neuropathy",
  "protocolDocument": {
    "nctId": "NCT06048471",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2019-09-01",
    "uploadDate": "2023-09-15T01:27",
    "size": 152878,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT06048471/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "NA"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "DOUBLE",
  "enrollmentInfo": {
    "enrollmentCount": 14,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2020-04-01",
    "completionDate": "2023-09-22",
    "primaryCompletionDate": "2023-09-22",
    "firstSubmitDate": "2020-03-02",
    "firstPostDate": "2023-09-21"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion criteria:\n\n* Patients with histologically verified colorectal cancer and adjuvant treatment with a platin derivate (e.g., cisplatin, oxaliplatin): This group was chosen due to relatively high risk of neuropathy due to this special therapeutic agent 1,9.\n* Cumulative dose of at least 3 cycles\n* Interval of 2 weeks since the last chemotherapeutic cycle in order to prevent false worsenings due to delayed neurotoxic effects\n* Life expectancy of at least 3 months\n* Stable medication (no changes of especially pain medication during the study)\n* Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0-2 (that is, the capability to walk and to spend less than 50% of waking hours sitting or lying)\n* Ability to walk (with or without aids)\n* European Organisation for Research and Treatment of Cancer (EORTC) common toxicity criteria (CTC) peripheral sensory neuropathy grade 1 or 2\n* Intensity of paresthesias of 3/10 or higher on the Numeric Rating Scale (NRS)\n\nExclusion criteria:\n\n* Prevalent neuropathy of different etiology\n* Serious central-neurological or psychiatric disorder that would interfer with a proper order of the study, according to the judgement of the investigators\n* Epilepsy\n* Minors or persons unable to give informed consent\n* Current neurotoxic medication\n* Implanted pacemakers or defibrillators\n* Pregnancy\n* Wounds in the area to be treated, acute local or systemic infection\n* Peripheral arterial occlusive disease \\> grade 2",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Intensity of paresthesia",
        "description": "NRS scale",
        "timeFrame": "5 weeks"
      }
    ],
    "secondary": [
      {
        "measure": "health related Quality of life (QOL), detailed symptroms of neuropathy",
        "description": "EORTC C30, CIPN 20, Neuropathy symptom scale (NSS), NRS scales",
        "timeFrame": "5 weeks"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 1,
      "otherCount": 0,
      "totalCount": 2
    },
    "studyDesign": {
      "phases": [
        "NA"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 44,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:30:50.687Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}